Vorinostat in solid and hematologic malignancies

Vorinostat (Zolinza(®)), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic th...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Siegel, David, Hussein, Mohamad, Belani, Chandra, Robert, Francisco, Galanis, Evanthia, Richon, Victoria M, Garcia-Vargas, José, Sanz-Rodriguez, Cesar, Rizvi, Syed
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2009
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2731787/
https://ncbi.nlm.nih.gov/pubmed/19635146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-2-31
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items